Yesterday, FDA approved Impavido to treat the tropical disease leishmaniasis, which is caused by a parasite transmitted to human through fly bites. Leishmaniasis mainly occurs in people who live in the tropics and subtropics and U.S. patients acquire the disease when traveling to those area. This is the first drug approved by the FDA to treat cutaneous and mucosal leishmaniasis and it has been known as miltefosine outside of the US. FDA had granted Impavido priority review and an orphan drug designation to allow scarce treatments for this rare disease to be available to patients.
Have you heard of leishmaniasis before or seen other medications used to treat the disease? What do you do differently and how do you make sure patients get proper counseling for a medication you are filling for the first time?
For additional information, please visit Reuters
Image Courtesy of [ SweetCrisis]/FreeDigitalPhotos.net